Skip to navigation Skip to content

News

Share

Anxiety and Depression Linked to Cognitive Problems in MS and Other Disorders, Says New Study

January 29, 2019

SUMMARY

  • Researchers compared the association of depression and anxiety with results of cognitive tests in people with MS, inflammatory bowel disease and rheumatoid arthritis, and in anxious/depressed individuals who didn’t have an inflammatory disorder.
  • In people with any of the disorders, higher levels of anxiety were associated with slower information processing speed, decreased verbal learning, and decreased working memory. Higher levels of depression were associated with decreased information processing speed.
  • These findings emphasize the importance of recognizing and managing anxiety and depression, which may reduce their impacts on cognitive functions.
  • The study was funded by the Canadian Institutes of Health Research, Crohn’s and Colitis Canada, and the Waugh Family Chair in MS at the University of Manitoba. The team (Christiane E. Whitehouse, BSc, a PhD, Dalhousie University, Halifax, Nova Scotia,  Ruth Ann Marrie, MD, PhD, University of Manitoba, Winnipeg) and others published their findings in Neurology (published online January 29, 2019).

DETAILS

Background: Depression and anxiety are commonly experienced symptoms in people who have multiple sclerosis. Several studies have suggested that depression and anxiety affect cognition (mental processes and actions), although findings have been inconsistent. This is important because impairment of cognitive functions -- including information processing speed, verbal learning, executive function, and recall and/or working memory -- affects the majority of individuals living with MS and can impact their relationships, employment, and many other activities. If there is a connection, interventions that address depression and anxiety may help to diminish their negative impacts on cognitive functions and on quality of life.

The Study: Investigators compared the association of depression and anxiety with cognitive impairment in people with MS and other inflammatory disorders (inflammatory bowel disease and rheumatoid arthritis), as well as on people who have depression and anxiety but not an inflammatory disease. A total of 964 participants from Manitoba, Canada, split among the four conditions, completed a psychiatric interview and psychological and cognitive tests. Participants were predominantly female Caucasians, with an average age from 43 to 59. Three-quarters of the participants with MS had relapsing-remitting MS, just under 20% had secondary progressive MS, and 9% had primary progressive MS.

Results: In all groups, higher levels of anxiety were associated with slower information processing speed, and decreases in verbal learning and working memory performance. Higher levels of depression were associated with slower information processing speed. All four groups showed more cognitive impairment than normally observed in the general population.

Experiencing both anxiety and depression was not more likely than either condition alone to predict cognitive deficits.

The study’s limitations include a lack of healthy controls, as well as having more women than men without looking at sex-specific risks for cognitive problems.

The team (Christiane E. Whitehouse, BSc, a PhD, Dalhousie University, Halifax, Nova Scotia, and Ruth Ann Marrie, MD, PhD, University of Manitoba, Winnipeg) and others published their findings in Neurology (published online January 29, 2019).

Conclusions: The results show that problems in thinking and remembering may, in part, be related to having anxiety and/or depression. Further research is needed to determine whether successfully treating anxiety and depression can reduce their impacts on cognitive functions. The National MS Society is funding several studies on psychosocial issues in MS, including a study testing an online program for reducing depression.

The findings emphasize the importance of recognizing and managing anxiety and depression, particularly anxiety which has received less attention than depression in studies of MS. Fortunately, treatments are available to diminish the effects of depression and anxiety. Professional counseling and support groups can be very helpful in dealing with these symptoms, and medication may also be needed to obtain relief.

Read More

Learn more about emotional health

Learn about cognitive changes

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867.

Share


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.